EHA 2021 | Outcomes of haplo-TBF versus MUD-FB in AML
Ali Bazarbachi, MD, American University of Beirut Medical Center, Beirut, Lebanon, talks on outcomes for patients with acute myeloid leukemia (AML) who receive haploidentical transplant with thiotepa-busulfan-fludarabine (haplo-TBF) conditioning, compared to those who receive transplant from a matched unrelated donor with fludarabine-busulfan conditioning (MUD-FB). Data from 708 AML patients who received haplo-TBF was compared to data from 2083 patients who received MUD-FB in a retrospective analysis. The analysis reported that haplo-TBF in patients with AML in first complete remission (CR1) significantly increased non-relapse mortality, but did not affect the incidence of relapse, leukemia-free survival (LFS), overall survival (OS) or relapse-free survival (RFS). For patients with AML in second complete remission (CR2), haplo-TBF significantly increased non-relapse mortality and decreased the relapse incidence, but did not influence LFS, OS or RFS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
